论文部分内容阅读
目的探讨和分析低分子肝素钙联合桂哌齐特治疗进展型脑梗死,总结疗效及临床应用价值。方法回顾性分析本院4年多来住院治疗的患者120例进展型脑梗死的患者随机分为治疗组和对照组各60例,在维持原有一般治疗基础上,治疗组给予低分子肝素钙5000IU,脐周皮下注射,每12h一次,桂哌齐特320mg静脉滴注,均连续应用14d;对照组低分子肝素钙联合复方丹参,应用14d,进行临床疗效评定。结果治疗组显效率和总有效率均明显优于对照组,不良反应没有增加,差异有统计学意义,P<0.05。结论低分子肝素钙联合桂哌齐特治疗进展性脑梗死疗效较好,毒副作用少,值得推广。
Objective To investigate and analyze low molecular weight heparin combined with cinepazide in treatment of advanced cerebral infarction, and to summarize the curative effect and clinical value. Methods A retrospective analysis of our hospital over 4 years hospitalized patients with 120 cases of progressive cerebral infarction were randomly divided into treatment group and control group of 60 patients, while maintaining the original general treatment, the treatment group given low molecular weight heparin 5000IU, umbilical subcutaneous injection, once every 12h, cinepazide 320mg intravenous drip, were continuously applied for 14d; control group of low molecular weight heparin combined with compound Salvia, application of 14d, the clinical efficacy evaluation. Results The effective rate and total effective rate of the treatment group were significantly better than the control group, the adverse reaction did not increase, the difference was statistically significant, P <0.05. Conclusion Low molecular weight heparin combined with cinepazide is effective in the treatment of patients with progressive cerebral infarction and has few side effects and is worth popularizing.